{
  "source": "PA-Notification-Wainua.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1434-2\nProgram Prior Authorization/Notification\nMedication Wainua™ (eplontersen)\nP&T Approval Date 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nWainua (eplontersen) is a transthyretin-directed antisense oligonucleotide indicated for the\ntreatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in\nadults.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Wainua will be approved based on all of the following criteria:\na. Diagnosis of hATTR amyloidosis with polyneuropathy\n-AND-\nb. Patient has a pathogenic TTR mutation (e.g., V30M)\n-AND-\nc. Patient is not receiving Wainua in combination with either of the following:\n(1) Oligonucleotide agents [e.g., Onpattro (patisiran), Amvuttra (vutrisiran),\nTegsedi (inotersen)]\n-OR-\n(2) Transthyretin stabilizer [e.g., Vyndaqel/Vyndamax (tafamadis), Attruby\n(acoramidis)]\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Wainua will be approved based on both of the following criteria:\na. Documentation of positive clinical response to Wainua therapy\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\nb. Patient is not receiving Wainua in combination with either of the following:\n(1) Oligonucleotide agents [e.g., Onpattro (patisiran), Amvuttra (vutrisiran),\nTegsedi (inotersen)]\n-OR-\n(2) Transthyretin stabilizer [e.g., Vyndaqel/Vyndamax (tafamadis), Attruby\n(acoramidis)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or the",
    "l and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Wainua [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September\n2024.\nProgram Prior Authorization/Notification – Wainua™ (eplontersen)\nChange Control\n2/2024 New program.\n2/2025 Added Attruby to Vyndaqel/Vyndamax and relabeled as transthyretin\nstabilizer agents not to be used in combination. Updated reference.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}